Protein Biomarker Producer Revolutionizes Early Detection of Gastric and Stomach Cancer
Published: Sep 7th, 2011
FOR IMMEDIATE RELEASE
PROTEIN BIOMARKER PRODUCER REVOLUTIONIZES EARLY DETECTION OF GASTRIC STOMACH CANCER
Lee BioSolutions Manufactures Purified Pepsinogen I and II, Key Components in Serum Pepsinogen Tests
ST. LOUIS (Sept 7, 2011) Lee BioSolutions, an international producer and supplier of high purity proteins, biological, biochemicals, antibodies and coenzymes, today announced a major scientific breakthrough. The St. Louis-based biotechnology firm recently developed a proprietary process to effectively and efficiently purify and stabilize two important gastric cancer protein biomarkers. As a result, Lee is mass producing Pepsinogen I and Pepsinogen II, critical components in serum pepsinogen tests that will revolutionize early detection of stomach and gastric cancer.
According to American Association for Cancer Research (AACR), stomach cancer is the second-leading cause of cancer-related deaths worldwide and the top cause in Eastern Asia, which comprises China, Japan, Taiwan and Korea. Studies have shown that if the disease is detected early, patients five-year survival rates increase 90 percent. Asian and European governments have been advocating mass screenings for decades, but traditional upper endoscopy procedures are painful, invasive and expensive. Lee\'s new Pepsinogen I and Pepsinogen II production capabilities enables international diagnostics companies to quickly manufacture serum pepsinogen tests, which are affordable and easy to administer. Lee has scaled up production to meet global market demand.
\"Gastric cancer screening using the pepsinogen filter test is the preferred method of cancer detection,\" said Burton Lee, president of Lee BioSolutions. \"The challenge to-date has been producing large volumes of tests efficiently and affordably. Recently, Lee\'s research and development team cracked the code for purifying and stabilizing two very important gastric and stomach cancer protein biomarkers, Pepsinogen I and Pepsinogen II, primary components in serum pepsinogen tests. We now have the expertise, processes and manufacturing capacity to produce enough of these biomaterials to make a significant impact.\"
Serum pepsinogen tests for gastric cancer enable healthcare providers to identify high risk patients for further monitoring. Not only do the tests increase survival rates by 90 percent but they also decrease the cost of mass screening programs. Lee currently has clients in Eastern Asia and Europe that plan to produce, distribute and administer the tests.
About Lee BioSolutions, Inc.
Lee BioSolutions is an international producer and supplier of high purity human, animal and recombinant proteins, biological fluids, biochemicals, antibodies and coenzymes. Headquartered in St. Louis and founded in 1981, the biotechnology firm serves academic and scientific researchers as well as IVD manufacturers worldwide. Lee BioSolutions produces and processes the raw biomaterials used in drug discovery and development, laboratory equipment calibration, clinical diagnosis and product testing. These include human neutrophil elastase, human myeloperoxidase isoform c, alpha fetoprotein, beta 2 microglobulin, and amylase. The company is ISO 9001:2008 certified, FDA registered and meets USDA guidelines. To learn more about Lee BioSolutions visit www.LeeBio.com or call 314-968-1091.
